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ABSTRACT  
Pituicyte stellation in vitro represents a useful model with which to study morphological changes that occur in 
vivo in these cells during times of high neurohypophysial hormone output. This model has helped us establish 
the hypothesis of a purinergic regulation of pituicyte morphological plasticity. We first show that ATP induces 
stellation in 37% of pituicytes, an effect that is secondary to the metabolism of ATP to adenosine. Adenosine-
induced stellation of pituicytes appears to be mediated by A1-type receptors. The effect is independent of 
intracellular calcium and does not involve the mitogen-activated protein kinase pathway. The basal (nonstellate) 
state of pituicytes depends on tonic activation of a Rho GTPase because both C3 transferase (a Rho inhibitor) 
and Y-27632 (an inhibitor of p160Rho kinase) can induce stellation. Lysophosphatidic acid, a Rho activator, 
blocks the morphogenic effect of adenosine dose-dependently. Using a specific RhoA pull-down assay, we also 
show that downregulation of activated RhoA is the key event coupling A1 receptor activation to pituicyte 
stellation, via F-actin depolymerization and microtubule reorganization. Finally, both vasopressin and oxytocin 
can prevent or reverse adenosine-induced stellation. The effects of vasopressin, and those of high concentrations 
of oxytocin, are mediated through Vla receptors. Placed within the context of the relevant literature, our data 
suggest the possibility of a purinergic regulation of pituicyte morphological plasticity and subsequent modulation 
of hormone release, with these hormones providing a negative feedback mechanism. 
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INTRODUCTION 
The morphological plasticity of glial cells in the hypothalamus-neurohypophysis (HNH) axis may represent an 
important regulatory system of neurohypophysial hormone release. During physiological conditions such as 
lactation or dehydration, i.e., conditions that require a high output of oxytocin (OXT) or vasopressin (AVP), 
morphological changes are observed at the level of both hypothalamic astrocytes and neurohypophysial 
pituicytes. For instance, astrocytes withdraw from between oxytocinergic neurons throughout the hypothalamus, 
which, through an increase in the number of contacts between neuronal membranes, may promote excitability 
and optimize hormone release (reviewed in Theodosis and Poulain, 1987, 1993). In the neurohypophysis, 
pituicytes retract from perivascular spaces, facilitating access of the secreting terminals to the basal lamina and 
release of their hormonal contents into the blood (reviewed in Theodosis and Macvicar, 1996; Hatton, 1999). 
Explant cultures represent a convenient means of studying the mechanisms of morphological plasticity in 
pituicytes. With appropriate stimulation, these cells can switch from a flat, processless shape to a rounded, 
stellate morphology in a manner reminiscent of that occurring in vivo upon stimulation of the HNH axis 
(reviewed by Hatton, 1988). One such stimulation that is now well established concerns activation of β-
adrenergic receptors, which has been shown to induce stellation in pituicyte explants (Bicknell et al., 1989), as 
well as corresponding morphological changes in a whole neural lobe preparation (Luckman and Bicknell, 1990). 
Several lines of evidence also suggest the possibility of a purinergic regulation of pituicyte plasticity, including 
the presence on these cells of purinergic receptors whose function is unresolved (Loesch et al., 1999; Troadec et 
al., 1999), the observation that ATP can be released from neurohypophysial terminals (Gratzl et al., 1980; 
Zimmermann, 1994; Sperlágh et al., 1999), and previous data suggesting that adenosine can induce stellation of 
rat pituicytes (Miyata et al., 1999) and astrocytes (Abe and Saito, 1998). We therefore studied the effects of 
endogenous and pharmacological ligands of purinergic receptors on pituicyte stellation in vitro and sought to 
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gain insight into the receptor subtypes and transduction mechanisms involved herein. To extend the 
physiological relevance of our findings, we also studied the action of AVP and OXT on stellation, suggesting a 
model for the concerted regulation of morphological plasticity of pituicytes in vivo. Most of these results have 
been reported at two recent meetings (Rosso et al., 2001a,b). 
MATERIALS AND METHODS  
Pituicyte Explant Cultures 
Adult Wistar rats (150-200 g) were anesthetized with CO2 and decapitated in accordance with French/ European 
ethical guidelines. For each culture, 4-6 hypophyses were placed in Hank's balanced salt solution (HBSS) (Gibco 
#14025) supplemented with 10 mM HEPES, 0.5 mg ml-1 bovine serum albumin (BSA), 100 U ml-1 penicillin, 
and 100 µg ml-1 streptomycin. The posterior lobe was separated from the anterior and intermediate lobes under a 
dissecting microscope and was divided into ~20 pieces. For morphological studies, each piece of tissue was 
placed in a 35-mm plastic dish coated with 0.05 mg ml-1 collagen and containing DMEM medium (Gibco 
#52100) supplemented with 1.2 gl-1 NaHCO3 and 10% fetal calf serum (FCS). For Rho assays, five tissue pieces 
were plated in 60-mm dishes. Cultures were maintained at 37°C in an incubator supplied with a [5% CO2/95% 
air] humidified atmosphere. The medium was replaced every 2-3 days. All experiments were performed on cell 
cultures after 8-12 days in vitro, at which time a monolayer of pituicytes had spread 5-10 mm from the explant. 
Control experiments (n = 10) performed as previously published by this laboratory (Troadec et al., 1999) showed 
that >95% of the cells were GFAP-positive. 
Morphological Analysis 
Because of the inhibitory effect of serum on stellation, cells were switched to a serum-free medium 1 h before 
experiments, a standard procedure followed by most investigators (e.g., Ramsell and Cobbett, 1997; Abe and 
Saito, 1998). Unless otherwise stated, all drugs or their vehicle as control were added 1 h (37°C) before image 
acquisition. The latter was performed with either a CCD camera (Dage MTI) and Axon Imaging Workbench 2.2 
software for kinetic studies, or a digital still camera and Adobe Photoshop software for cell counting. Digitized 
images were coded with respect to treatment in order to perform blind counting. Cells were considered stellate 
when they displayed ≥2 processes (Ramsell and Cobbett, 1997). For each culture dish, the proportion of stellate 
cells was assessed by counting 100-200 cells at 10× magnification (Fig. 1A) over five arbitrarily chosen areas 
0.9 × 0.7 mm wide, and taking the resulting average. Differences between treatment groups were evaluated with 
analysis of variance followed by a Bonferroni post hoc test, with significance set at P < 0.05. 
Calcium Imaging 
Intracellular Ca2+ ([Ca2+]i) was measured with the ratiometric, membrane-permeable, fluorescent probe Fura-2 
AM. Briefly, pituicyte cultures were incubated 45 min at 37°C in the presence of 5 µM Fura-2 AM + 0.01% 
pluronic acid. During experiments, a culture dish was continuously superfused with Ringer's solution (3 ml/min). 
These experiments were performed on the stage of an inverted microscope (Zeiss ICM 405) equipped with a Xe 
lamp and a rotating filter set allowing 350/380-nm excitation. Axon Imaging Workbench 2.2 software was used 
to drive the filter wheel, acquire fluorescence images and process data. For any given experiment, fluorescence 
signals were averaged from 10-15 cells defined as "regions of interest". Free [Ca2+]i was estimated from a 
calibration procedure using a "zero-Ca" solution (3 mM EGTA + 2 µM ionomycin) and a Ca-saturated solution 
(3 mM CaCl2 + 2 µM ionomycin). F350/380 ratios were converted to free [Ca2+]i using the Grynkiewicz 
equation (see Hatton et al., 1992). Drugs were applied locally via a miniperfusion system. 
ERK and p38 Phosphorylation Assays (Western Blot Analysis) 
Serum-free cultures were stimulated with ATP or adenosine (or vehicle) for 10 min, washed in phosphate-
buffered saline (PBS) at 4°C, then exposed to a lysis buffer (20 mM Tris, 137 mM NaCl, 2 mM EDTA, 25 mM 
β-glycerophosphate, 1 mM Na-orthovanadate, 2 mM NaPPi, 1 mM PMSF, 10% glycerol, 2% Triton X-100; pH 
7.5) supplemented with the protease inhibitors aprotinin (2 µg/ml), leupeptin (10 µM), and AEBSF (1 mM). Cell 
lysates were scraped off culture dishes and centrifuged (14,000g; 10 min at 4°C) to recover cytosolic proteins 
from the supernatant. Proteins were then quantified based on Bradford reaction (Bio-Rad kit). Because of the low 
yield (~0.4 µg/ml protein) of our samples, proteins were precipitated with 5 vol/vol acetone. The resulting 
samples were stored 30 min at -80°C, subsequently centrifuged (8,500g; 3 min at 4°C), and pellets were 
resuspended in adequate volumes of standard denaturing buffer. Proteins (25 µg/lane) were separated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) electrophoresis at 100 V for 1 h on 10% acryl-
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amide gels, transferred to nitrocellulose membranes (Amersham's Hybond-C), and stained with Ponceau red to 
verify even transfer. The membranes were then saturated with 5% skim milk in PBS containing 0.1% Tween 20 
for 1 h at RT, and incubated with primary antibodies diluted 1:2,000 for anti-phospho p38 (M8177 from Sigma) 
and 1/10,000 for anti-phospho ERK (M8159 from Sigma) in PBS containing 1% skim milk and 0.1% Tween 20. 
After 3 rinses in PBS/Tween 20, membranes were incubated for 1 h at RT with secondary antibody (goat anti-
mouse coupled to horseradish peroxidase [HPO]) diluted 1:5,000 in the same PBS-skimmed milk solution. After 
secondary antibody removal, blots were developed using the enhanced chemi-luminescence (ECL) detection 
system (Amersham). 
Rho GTPase Activity Assay 
The RhoA assay was performed on pituicytes under the following conditions, using 5 60-mm culture dishes per 
condition: (1) control, i.e., 70 min without serum; (2) 60 min without serum followed by 10-min exposure to 10 
µM adenosine; and (3) positive control, i.e., 60 min without serum followed by 10 min in the presence of 10% 
serum. The cells were lysed in buffer A (25 mM HEPES [pH 7.3], 150 mM NaCl, 5 mM MgCl2, 0.5 mM EGTA, 
0.5% Triton X-100, 4% glycerol, 20 mM β-glycerophosphate, 10 mM NaF, 2 mM Na-orthovanadate, 5 mM 
dithiothreitol, and protease inhibitors) for 10 min at 4°C; the Triton X-100 insoluble material was removed by 
centrifugation (10 min; 10,000 rpm), and the lysates were incubated for 40 min at 4°C with 20 µg of bacterially 
produced GST-RBD (glutathione-S-transferase-Rho binding domain), which was bound to glutathione-coupled 
Sepharose beads (Ren et al., 1999). Beads were washed 4 times in buffer A, resuspended in Laemmli buffer, and 
proteins were separated by SDS-PAGE on 12% acrylamide gels. RhoA was detected by Western blotting, using 
a specific antibody (Rho A (26C4): sc-418, Santa Cruz Biotechnology). Before incubation with the beads, 50-µl 
aliquots were removed from each sample for determination of total RhoA. 
Cytoskeleton Labeling 
Actin filaments were labeled with FITC-coupled phalloidin (100 ng/ml), and microtubules were labeled with an 
anti-β-tubulin monoclonal antibody (Sigma) diluted 1:200. After exposure to specific control and test conditions 
as indicated, the cells were fixed with 3% paraformaldehyde + 2% sucrose at 37°C, washed 3 times in PBS, 
permeabilized for 4 min in PBS + 0.2% Triton, and again rinsed three times in PBS and saturated 15 min in PBS 
+ 5% serum. Primary antitubulin antibody was applied for 2 h in a wet chamber at room temperature. After four 
rinses and a new saturation with PBS + 5% serum for 15 min, the cells were incubated with anti-mouse IgG 
secondary antibody (Alexa 594, Molecular Probes, Eugene, OR) with or without FITC-coupled phalloidin for 1 
h at RT. After four rinses, the cells were mounted on slides in the presence of Citifluor for observation on an 
epifluorescence microscope. 
Drugs 
All drugs that were used are listed in Table 1. We carefully checked that neither the solvents nor the receptor 
antagonists or enzyme inhibitors that we tested had any significant effect of their own on pituicytes (≤5% 
stellation). All drugs were from Sigma except bestatin (Boehringer-Roche), PP2 (Calbiochem), and the 
following compounds, which were given to us by the indicated persons: C3 toxin, P. Boquet (INSERM U-452, 
Nice, France); Y-27632, A. Yoshimura (Yoshitomi Pharmaceutical Industries, Osaka, Japan); SR 49059 and SR 
121463, C. Serradeil-Le Gal (Sanofi-Synthélabo, Toulouse, France); CL 12-27, M. Manning (Medical College of 
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TABLE 1. List of drugs used 
Drug Chemical name Stock Solvent 
Adenosine  10 mM H2O 
Alloxazine  10 mM DMSO 
Apyrase  300 U/ml Culture medium
ARL67156 6-N,N-diethyl-β-γ-dibromomethylene-D-adenosine-5-triphosphate 10 mM Culture medium
ATP Adenosine triphosphate 100 mM H2O 
ATP-7-S Adenosine 5'-0-(3-thiotriphosphate) 10 mM DMSO 
BAPTA-AM l,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
tetrakis(acetoxymethyl ester) 
10 mM DMSO 
Bestatin  10 mM DMSO 
Bradykinin  0.1 mM H2O 
C3 transferase  30 mg/ml H2O 
Captopril  0.1 mM H2O 
CGS-21680 (2-p-(2-carboxyethyl)phenethylamino-5'-N-
ethylcarboxamidoadenosine 
10 mM DMSO 
CL 12-27 ( l-deamino-4-cyclohexylalanine)arginine vasopressin 1 mM H2O 
CPA N6-cyclopentyladenosine 10 mM H2O 
Dibutyryl cAMP Dibutyryl cyclic adenosine monophosphate 10 mM Culture medium
DMPX 3,7-dimethyl-1-propargylxanthine 10 mM DMSO 
DPCPX l,3-dipropyl-8-cyclopentylxanthine 10 mM DMSO 
Forskolin  10 mM Ethanol 
H89 N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide 0.1 mM DMSO 
IB-MECA N6-(3-iodobenzyl)-9-[5-(methylcarbamoyl)-β-D-ribofuranosyl]adenine 10 mM DMSO 
Ionomycin  10 mM DMSO 
Lysophosphatidic 
acid 
 10 mM H2O 
MRS 1191 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-l,4-(±)-
dihydropyridine-3,5-dicarboxylate 
10 mM DMSO 
Oxytocin  0.5 mM H2O 
PD98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 10 mM DMSO 
Pertussis toxin  50 µg/ml a
Phosphoramidon  10 mM H2O 
PP2 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine 5 mM DMSO 
PPADS Pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid 10 mM H2O 
SB203580 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-
imidazole 
10 mM DMSO 
SR 121463 1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzene sulfonyl]-5-ethoxy-
3-spiro-[4-(2-morpholinoethoxy)cyclohexane]indoline-2-one 
10 mM DMSO 
SR 49059 (2S) 1-[(2R3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-
dimethoxybenzene-sulfonyD-3-hydroxy-2,3-dihydro-1H-indole-2-
carbonyl]pyrrolidine-2-carboxamide 
10 mM DMSO 
Suramin  10 mM Culture medium
Vasopressin  0.5 mM H2O 
Y-27632 (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide 7 mM H2O 
DMSO, dimethylsulfoxide.  
aSupplied as a solution. 
RESULTS 
ATP and Adenosine Effects on Pituicyte Stellation 
Our initial experiments indicated that ATP was able to induce pituicyte stellation (Fig. 1B,D). However, this 
effect was not reproduced by the nonhydrolyzable analogue ATP-γ-S (Fig. 1D). Given the presence of ecto-
ATPases on the outer surface of the pituicyte plasma membrane (Thirion et al., 1996), we surmised that the 
effects of ATP might be due to its hydrolytic products. Indeed, adenosine (as well as ADP and AMP; not shown) 
was found to induce a more extensive stellation of pituicytes and at a lower concentration than ATP (Fig. 
1A,C,D). This difference might reflect partial hydrolysis of ATP, as the effects of the latter were substantially 
slower (~60 min) than those of adenosine (~30 min; Fig. 1B,C). To test our hypothesis, we performed two 
experiments. First, we coapplied ATP with apyrase to accelerate the rate of ATP hydrolysis artificially; under 
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these conditions, the effects observed with ATP were significantly stronger than when it was applied alone (Fig. 
1D). Second, we coapplied ATP with ARL67156, an ecto-ATPase inhibitor; in these conditions conversely, the 
effect of ATP was completely blocked (Fig. 1D), clearly demonstrating that hydrolysis was a necessary step for 
ATP to induce stellation. In fact, the nonselective P2 receptor (i.e., ATP receptor) antagonists PPADS and 
suramin failed to block the effect of ATP (Fig. 1D), whereas an A1 (i.e., adenosine receptor) antagonist was 
effective (see below). 
Adenosine Receptor Subtype Specificity 
We then carried out a pharmacological characterization to identify the adenosine receptor subtypes involved in 
the stellation process. The results are summarized in Figure 2A. CPA, an A1 agonist, and IB-MECA, an A3 
agonist, induced stellation to an extent comparable to that obtained with adenosine, while CGS-21680, an A2A 
agonist, was without effect. Confirming this latter result, DMPX, an A2A antagonist, did not prevent adenosine-
induced stellation. As there are no A2B-selective agonists (Ralevic and Burnstock, 1998), we tested a relatively 
specific A2B antagonist, alloxazine, which failed to block adenosine-induced stellation. Surprisingly, DPCPX, an 
A1 antagonist, completely blocked the effects of both adenosine and IB-MECA (Fig. 2A), suggesting that either 
IB-MECA or DPCPX exert nonspecific effects on A1 or A3 receptors, respectively. However, the fact that MRS 
1191, an A3 antagonist, failed to block the effects of either adenosine or IB-MECA (Fig. 2A) strongly suggests 
that IB-MECA has a nonspecific action at A1 receptors. In an attempt to optimize the selectivity of DPCPX by 
reducing its concentration, we tested 100 nM DPCPX against 10 µM adenosine (n = 8), CPA (n = 3) or IB-
MECA (n = 3). Unfortunately, at this dose the antagonist failed to block either agonist (≥75% stellation), 
probably because its Ki is too close to the KD of the agonists. DPCPX (10 µM) also completely blocked the 
effects of ATP (Fig. 2A), ADP and AMP (not shown), a further argument in favor of an indirect, adenosine-
mediated effect of ATP. 
Transduction Mechanisms Involved in Adenosine Receptor Activation 
Having identified the receptor subtype involved, we aimed to investigate the transduction mechanism 
responsible for the morphogenic effects of purinergic agonists. We have previously reported that adenosine can 
raise ([Ca2+]i) in pituicytes (Peteri-Brunbäck et al., 2001). Using the consistency of bradykinin responses as a 
standard, we found that adenosine induces either a strong [Ca2+]i response, a weak response or no response at all, 
with each of these occurrences observed in roughly equal proportions (~1/3 cells; Fig. 3A,B,C). We thus tested 
whether a Ca2+ signal could mediate the induction of stellation. Contradicting this hypothesis, we found that the 
Ca2+ ionophore ionomycin was without effect (Fig. 2B). Furthermore, preincubation of the cells with the 
membrane-permeable Ca2+ chelator BAPTA-AM for 50 min failed to prevent the morphogenic effect of 
adenosine (Fig. 2B). 
We have also reported that in pituicytes adenosine is able to stimulate mitogen-activated protein kinase (MAPK) 
pathways (Peteri-Brunbäck et al., 2001), which are known to be involved in cell differentiation. Figure 3D shows 
results obtained with both adenosine and ATP, which has previously been shown to stimulate MAP kinases in 
astrocytes via P2Y receptors (Neary et al., 1996). Nevertheless, we ruled out involvement of these pathways in 
pituicyte stellation, since neither PD98059, an inhibitor of MEK (MAP/ ERK [extracellular signal-regulated] 
kinase), nor SB203580, an inhibitor of p38 kinase, antagonized the morphogenic effect of adenosine (Fig. 2B), 
CPA, or IB-MECA (not shown). 
It has previously been suggested that a raise in cytoplasmic cAMP is an important intermediary step in pituicyte 
stellation (Ramsell and Cobbett, 1997). We have confirmed that both forskolin (10 µM), an adenyl-cyclase 
activator, and dibutyryl cAMP (1 mM), a cell-permeant analogue of cAMP, can induce stellation (68 ± 4% and 
57 ± 6%, respectively; n = 8 each; P < 0.05 compared with control). These results may seem at odds with the 
effects of A1 receptor stimulation, which have been described as transducing through Gi protein activation, 
inhibition of adenylcyclase and cAMP decrease (Ralevic and Burnstock, 1998). This, together with the fact that 
neither pertussis toxin, a Gi/o protein inhibitor, nor H89, a protein kinase A (PKA) inhibitor, blocked adenosine-
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Fig. 1. Effects of ATP and adenosine on rat pituicyte stellation. A: Cultured pituicytes in control conditions (serum-free 
medium; left) and 1 h after treatment with 10 µM adenosine (Ado; right). B,C: Photographs of cultured pituicytes (fixed field) taken after 
exposure to ATP (B) or adenosine (C) for the time indicated in upper right corner (in min). D: Summary of results (mean ± SE) obtained in 
the various conditions indicated. Apyrase, ARL67156, PPADS, and suramin were applied 10 min before ATP. Concentrations: ATP, ATP-γ-
S, and PPADS, 100 µM; adenosine, 10 µM; apyrase, 30 U ml-1; ARL67156 and suramin, 300 µM. Apyrase alone did not induce any 
significant stellation. In this and subsequent graphs, the number on top of each bar represents the number of culture dishes counted. a, 
significantly different from control; b, significantly different from ATP. A, 500 × 500 µm (×10 lens), B, C, 200 × 200 µm (×32 lens). 
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Fig. 2. Pharmacology of purinergic induction of rat pituicyte stellation. A: Pharmacology of adenosine receptor subtypes 
involved in stellation. Antagonists (DPCPX, DMPX, alloxazine, and MRS-1191) were applied 10 min before agonists. a, significantly 
different from CGS-21680; b, significantly different from CPA. B: Pharmacology of transduction pathways involved in adenosine receptor 
activation. BAPTA-AM was applied 50 min, PD98059 and SB203580 30 min, pertussis toxin (PTX) 12 h, and H89 15 min before adenosine 
application. All drugs were applied at 10 µM except ATP, 100 µM; ionomycin, 1 µM; PTX, 0.1 µg ml-1 and H89, 0.3 µM. PD98059 and 
SB203580 were also tested at 30 µM and yielded similar results. BAPTA-AM alone did not induce any significant stellation. *Significantly 
different from BAPTA-AM. 
 
 
Involvement of RhoA Inactivation in Adenosine-induced Pituicyte Stellation 
As it has previously been shown that astrocyte stellation is controlled by a member of the Rho family of proteins 
(Ramakers and Moolenaar, 1998), which are small GTPases involved in cytoskeleton rearrangement (Machesky 
and Hall, 1996), we tested whether this mechanism could transduce the morphogenic effects of adenosine in 
pituicytes. It should be noted that the "default," i.e., the basal state of cultured glia corresponds to the 
maintenance of actin stress fibers under the tonic activation of Rho (Ramakers and Moolenaar, 1998), implying 
that stellation should be the result of Rho inactivation. We found that Rho indeed was active in pituicytes 
because stellation could be induced with C3 transferase (Fig. 4), a Clostridium botulinum toxin that specifically 
inactivates Rho (Chardin et al., 1989; Machesky and Hall, 1996; Ramakers and Moolenaar, 1998). Further, 
similar results were obtained with Y-27632 (Fig. 4), a specific inhibitor of a Rho-associated protein kinase 
named p160ROCK and known to be the main downstream mediator of cytoskeletal changes (Uehata et al., 
1997). Conversely, when we treated pituicytes for 10 min with lysophosphatidic acid (LPA), a powerful Rho 
activator (Ramakers and Moolenaar, 1998), the drug dose-dependently prevented adenosine-mediated stellation 
(Fig. 4). By suggesting competition for a common signaling pathway, this result provides preliminary evidence 
in favor of our initial hypothesis that adenosine induces stellation via the Rho pathway. In contrast to LPA, the 
Src family kinase inhibitor PP2 failed to block adenosine-induced stellation (Fig. 4; see Discussion). 
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To confirm Rho involvement, we performed pulldown assays to monitor the activity of RhoA and thereby 
determine whether it was a target for the inhibitory action of adenosine in pituicytes. Figure 5 shows that the 
activated form of RhoA is greatly decreased after 10 min in the presence of adenosine. As expected, in control 
conditions, i.e., in serum-free medium, a basal activity is detected, which apparently suffices to maintain the 
fusiform shape of pituicytes. Conversely, addition of serum, which contains high amounts of LPA, enhances 
RhoA activity. 
Cytoskeletal Rearrangements During Adenosine-induced Pituicyte Stellation 
Next, we investigated the cytoskeletal changes that occur in pituicytes during adenosine-induced stellation. 
These changes consisted basically of actin rearrangement, with disappearance of stress fibers, and specific 
reassembly of microtubules within newly formed processes (Fig. 6), similar to results obtained by Miyata et al. 
(1999) upon stimulation with dibutyryl cAMP. We also compared the kinetics of the morphogenic effects 
elicited by adenosine and Y-27632. In both cases, significant alterations of actin fibers could be seen after 20 
min of treatment, while the whole process appeared to be completed within 30 min (Fig. 7). These results 
suggest that the limiting step in the time course of the stellation process lies between Rho inhibition and 
depolymerization of actin fibers. Thus, whatever the nature of the coupling mechanism between A1 receptor 
activation and RhoA inactivation, this initial step appears to be relatively fast, as also indicated by the shorter 
response time observed for adenosine-induced repression of activated RhoA (Fig. 5). 
 
Fig. 3. Effects of adenosine on pituicyte [Ca2+]i mobilization (A-C) and on MAP kinase pathways (D). Application 
of adenosine to pituicytes induced either a strong [Ca2+]i response comparable to that of bradykinin (A), a relatively weak response (B), or no 
response at all (C). Graphs show average [Ca2+]i levels from 9 (A), 11 (B), and 10 (C) experiments (note that each experiment itself is the 
average of 10-15 cells; see Methods). D: Both ATP and adenosine increase the activated (phosphorylated) form of p38 and ERK proteins. 
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Fig. 4. Involvement of Rho GTPase in rat pituicyte stellation. Lysophosphatidic acid (LPA) and PP2 were 
applied 10 min before adenosine. C3 toxin was applied for 24 h (Ramakers and Moolenaar, 1998); therefore, we also included a 
control count at this time point. Concentrations: Adenosine, 10 µM; LPA, as indicated (in µM); C3, 20 µg ml-1; Y-27632, 7 µM; PP2, 5 µM. 
*Significantly different from adenosine (0.1 µM LPA is also significantly different from 1 µM LPA). 
 
Fig. 5. Western blot showing adenosine-induced inhibition of RhoA activity in pituicytes. RhoA activity was detected 
with a pull-down assay; total RhoA is shown for reference (see Materials and Methods). Adenosine (10 µM) or serum were applied for 10 
min before cell lysis. Similar results were obtained in a duplicate experiment. 
 
 
Effects of AVP and OXT 
We then tested whether AVP and OXT might provide a negative feedback for the action of adenosine, and 
discovered that both hormones were capable of preventing, and more interestingly reversing, the effects of 
adenosine (Fig. 8). It should be mentioned that Espelt et al. (1998) previously found, using a different culture 
technique, that long-term treatment with AVP or OXT results in pituicytes devoid of processes. Comparing 
hormone potency, we noted that 10 nM OXT reversed stellation in only 17% cells, compared with 86% with 1 
nM AVP (n = 4; not shown). In order to elucidate the receptor subtype involved in these hormone effects, we 
tested SR 49059, a specific V1a antagonist, and SR 121463, a specific V2 antagonist (Serradeil-Le Gal, 1998). 
Whereas SR 121463 had no effect, SR 49059 antagonized the effects of both AVP and OXT (Fig. 8). 
Confirming involvement of V1a receptors, complete inhibition of stellation reversal was obtained with 100 nM 
SR 49059 against 10 nM AVP (72 ± 6% stellation; n = 4). In view of the unavailability of specific V1b 
antagonists, we tested whether CL 12-27, a relatively specific V1b peptidic agonist (Derick et al., 2001), would 
mimic the effects of AVP. In concentrations up to 25 nM, CL 12-27 did not reverse adenosine-induced stellation, 
which was obtained only at 1 µM, a concentration well beyond the threshold of selectivity of CL 12-27 for V1b 
versus other receptor subtypes (Derick et al., 2001). Finally, in view of the potential breakdown of AVP to 
potent metabolites (reviewed by Barberis and Tribollet, 1996), we checked for the effects of AVP in the presence 
of a cocktail of peptidase inhibitors (10-5 M bestatin + 10-6 M captopril + 10-5 M phosphoram-idon). No 
difference was seen in the effects of AVP alone or in the presence of peptidase inhibitors (Fig. 8), suggesting that 
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Fig. 6. Adenosine-induced reorganization of pituicyte cytoskeleton. Microphotographs show fluorescent labeling of F-actin 
(A,B) and tubulin (C,D) in control (A,C,E) and after exposure to 10 µM adenosine for 30 min (B,D,F). E,F: Actin/tubulin double-labeling 
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Fig. 7. Kinetics of pituicyte F-actin copolymerization in the presence of 10 µM adenosine (top) or 7 µM of the 
p160ROCK inhibitor Y-27632 (bottom) at the times indicated (min). Scale bar = 50 µm. [Color figure can be viewed in the 
online issue, which is available at www.interscience.wiley.com] 
 
 
Fig. 8. Blockade of adenosine-induced pituicyte stellation by vasopressin (AVP) and oxytocin (OXT). Cells were 
either pretreated with 500 nM hormone for 10 min (second and third bars) or exposed to 100 nM hormone for 20 min after stellation was 
induced with 10 µM adenosine (Ado) for 40 min (all remaining bars). No significant difference in stellation was found between 40 and 60 
min adenosine (P = 0.17; see also Fig. 1C). SR antagonists (both at 100 nM) and peptidase inhibitors were applied 5 min before hormones. 
CL 12-27 was applied at 25 nM following the same protocol as for AVP and OXT. a, significantly different from adenosine; b, significantly 




Our results suggest the existence of a purinergic regulation of morphological plasticity in pituicytes. A likely 
scenario would involve release of ATP from neurosecretory vesicles and nerve swellings of the HNH axis 
(Gratzl et al., 1980; Zimmermann, 1994; Sperlágh et al., 1999), hydrolysis of the nucleotide to adenosine by 
local ecto-nucleotidases (Thirion et al., 1996), and stimulation of pituicyte A1 receptors followed by Rho 
inactivation and depolymerization of actin stress fibers. The fact that the effects we observed with ATP are 
secondary to adenosine formation is demonstrated by several arguments: (1) the longer delay observed for these 
effects is more likely to involve time-dependent hydrolysis than different receptor kinetics; (2) these effects were 
insensitive to P2 receptor antagonists and completely blocked by DPCPX, an A1 receptor antagonist; (3) ATP-γ-
S, which is not hydrolyzable, essentially failed to induce stellation (the stellation observed in some cells with 
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ATP-γ-S may be due to a direct effect on A1 receptors (Ralevic and Burnstock, 1998); and (4) enhancing ATP 
hydrolysis with apyrase increased the effects of the nucleotide, while preventing endogenous hydrolysis with an 
ecto-ATPase inhibitor blocked them. 
All adenosine receptors are coupled to heterotrimeric G proteins, A1 receptor activation being known to 
transduce either via the Gi pathway, leading to adenyl-cyclase inhibition, or via the Gq pathway, leading to IP3 
production and Cai2+ mobilization (Ralevic and Burnstock, 1998). In our case, involvement of Cai2+ was clearly 
ruled out and cAMP stimulation rather than inhibition induced stellation; moreover, pertussis toxin, a Gi/o protein 
inhibitor, failed to block adenosine's effects. Similarly, involvement of a Gs protein is unlikely, since PKA 
inhibition did not prevent adenosine-induced stellation, and Abe and Saito (1998) demonstrated the absence of 
any change in cAMP concentration during adenosine-induced stellation of cortical astrocytes. Thus far, we then 
can postulate two coexisting pathways capable of inducing stellation, one used by adenosine, which is cAMP 
independent, and one used, e.g., by catecholamines (see below), which is cAMP dependent. 
We then attempted to correlate these effects with our recent finding that adenosine activates MAPK pathways in 
pituicytes (Peteri-Brunbäck et al., 2001). Indeed, Neary et al. (1996) showed that ATP, via P2 receptors, can 
both stimulate MAP kinases and induce stellation in astrocytes, suggesting a possible link between these events. 
In contrast, Abe and Saito (1998) demonstrated that in cortical astrocytes adenosine-induced stellation was not 
coupled to MAPK pathways. The latter results, therefore, are entirely consistent with our own, given the failure 
of MAPK specific inhibitors to prevent adenosine-induced stellation in pituicytes. 
Finally, we have gathered conclusive evidence that pituicyte morphological plasticity is under the control of 
RhoA GTPase, and that adenosine most likely induces stellation by inhibiting this protein. It is intriguing that the 
opposite seems to occur in neurons, in which A1 receptor activation leads to stress fiber formation via the Rho 
kinase pathway (Thevananther et al., 2001). Thus, A1/Rho coupling may constitute an important component of 
differentiation of the neuronal versus glial lineage. On the other hand, Abbracchio et al. (2001) have shown that 
in astrocytoma cells selective activation of A3-type adenosine receptors by a chloro derivative of IB-MECA 
induces the formation of actin stress fibers via Rho stimulation. Although it may not be relevant to compare 
transformed astrocytes with normal pituicytes, the potential discrepancy that adenosine would elicit conflicting 
effects if both A1 and A3 receptors were coexpressed in a given cell type might be resolved based on different 
affinity constants for adenosine, which might allow selective activation according to specific physiological 
demands (Ralevic and Burnstock, 1998). From these considerations, it is clear that the next important step will 
be to determine which adenosine receptor subtypes are expressed in various cell lineages (e.g., glial vs neuronal) 
or sublineages (e.g., astrocytes vs pituicytes). 
The other important issue concerns the mode of coupling of these receptors to the Rho pathway. Our results are 
novel with respect to the fact that A1 receptor-mediated stellation is effected via Rho inhibition. Recent reports 
(Arthur et al., 2000) indicate that RhoA activity is suppressed after integrin engagement by a Src-dependent 
mechanism involving tyrosine phosphorylation and stimulation of p190RhoGAP (a GTPase-activating protein 
that inactivates Rho). We do not believe that this is the case in our system since the Src family kinase inhibitor 
PP2 had no effect on adenosine-induced stellation. This conclusion is further supported by our finding that the 
response to adenosine could be overcome by treatment with the Rho activator LPA. This result would not be 
expected if activation of a RhoGAP were responsible for Rho inhibition by adenosine. 
The postulate that all adenosine receptors are coupled to heterotrimeric G proteins is consistent with the idea that 
Rho activity may be modulated by extracellular signals through heterotrimeric G proteins (Seasholtz et al., 
1999). We already excluded coupling with a Gi/o or Gs protein for A1 receptor-mediated stellation, even though it 
has been shown that PKA can inhibit Rho in lymphocytes (Lang et al., 1996). We also noted earlier that A1 
receptors may be coupled to Gq proteins. Interestingly, Safavi-Abbasi et al. (2001) hypothesized that activation 
of the Gq/protein kinase C (PKC) pathway may lead to RhoA inhibition in astrocytes. Thus, we plan to test 
whether this is the mechanism by which adenosine acting at A1 receptors induces pituicyte stellation, in which 
case we predict that a calcium-independent type of PKC would be involved. 
It should be noted that adenylcyclase-coupled catecholamine stimulation of β-adrenergic receptors (and 
subsequent cytosolic cAMP increase) also constitutes a route for pituicyte stellation (Hatton, 1999). This is 
particularly relevant because neurohypophysial hormones are in high demand under stress conditions. One can 
only surmise that at least two distinct pathways may operate in parallel. Given our present knowledge, it is 
possible to propose a concerted model accounting for the relationships between changes in pituicyte morphology 
and neurohypophysial hormone release. Thus, an initial stimulus (e.g., hypovolemia, hypertonicity) will trigger a 
primary response consisting of hypothalamic neuron firing and primary hormonal release from the 
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neurohypophysis; this might be aided secondarily by pituicyte morphological remodeling under the action of 
circulating catecholamines. Simultaneously, the primary release of secretory vesicles should also result in a high 
enough (tens of micromolar) concentration of extracellular ATP (Troadec et al., 1998) available to ecto-
nucleotidases for adenosine synthesis and further enhancement of the glial morphogenic process. In addition, it 
has been shown that ATP directly acting on P2X2 receptors of neurohypophysial terminals can enhance AVP 
release (Troadec et al., 1998). 
Thus, it appears that these events may represent a powerful amplification system tailored to the requirements of 
specific physiological situations. To abide by homeostatic principles, however, any such system must be 
endowed with a stop signal. In this regard, we have shown that AVP and OXT can reverse pituicyte stellation 
induced by adenosine, thereby potentially providing a negative feedback signal. These effects apparently are 
mediated through V1a receptors, which is consistent with the presence of functional V1 receptors on pituicytes, 
and with the fact that OXT might weakly activate these receptors (Hatton et al., 1992). In the hypothalamus, 
astrocytes change shape specifically in response to OXT (Theodosis et al., 1986). However, it is uncertain 
whether these changes, observed at the electron microscopic level, correspond to stellation or, on the contrary, 
elongation. Although the second case would be consistent with our results, we cannot exclude that astrocytes and 
pituicytes might behave differently. It remains to be determined whether reversal of stellation by AVP and OXT 
takes place via the same signal transduction pathways as induction of stellation by adenosine. 
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